China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Construction of a DPN Prediction Model Based on Multimodal Ultrasound Features of the T... Read More
China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Repeatability of artificial intelligence-based automatic measurement of peri-implant ma... Read More
China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Exercise Knowledge, Practices, and Fear of Movement in Patients Receiving Maintenance H... Read More
China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Acute Effects and Temporal Profile of a Combined Blood Flow Restriction and Bodyweight ... Read More
China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Application of Magnetic Navigation in Hepatolithiasis'. The following are the other rel... Read More
China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Study on the efficacy and mechanism of Sanqi Danshen tablets in the treatment of patien... Read More
China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'The CXCL16-CXCR6 axis drives CCR8 effector regulatory T cell accumulation and shapes th... Read More
China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Clinical Study on the Efficacy of Bencycloquidium Bromide Nasal Spray in Patients aft... Read More
China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of lBl362 for Heart F... Read More
China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Perioperative sintilimab, ipilimumab N01, and SOX for HER2-negative, PD-L1 CPS >=1, MSS... Read More